Adicet Bio, Inc. Operating Cash Flow
Adicet Bio, Inc. (ACET) reported Operating Cash Flow of -$41.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Adicet Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$19.82M.
- Adicet Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$21.49M.
- Adicet Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$20.91M.
- Adicet Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$22.31M.
- Adicet Bio, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$95.25M.
- Adicet Bio, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$92.38M.
- Adicet Bio, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$93.72M.
- Adicet Bio, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$44.77M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$19.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$41.31M 10-Q · filed 2026-08-05 | -$62.22M derived: sum of 3 quarters · filed 2026-08-05 | -$84.53M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$21.49M 10-Q · filed 2026-05-13 | -$42.40M derived: sum of 2 quarters · filed 2026-05-13 | -$64.71M derived: sum of 3 quarters · filed 2026-05-13 | -$91.34M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$20.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$43.22M derived: sum of 2 quarters · filed 2026-03-12 | -$69.85M derived: sum of 3 quarters · filed 2026-08-05 | -$95.25M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$22.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$48.94M derived: sum of 2 quarters · filed 2026-08-05 | -$74.34M 10-Q · filed 2025-11-05 | -$98.44M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$26.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$52.03M 10-Q · filed 2026-08-05 | -$76.13M derived: sum of 3 quarters · filed 2026-08-05 | -$98.14M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$25.40M 10-Q · filed 2026-05-13 | -$49.50M derived: sum of 2 quarters · filed 2026-05-13 | -$71.50M derived: sum of 3 quarters · filed 2026-05-13 | -$94.93M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$24.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$46.11M derived: sum of 2 quarters · filed 2026-03-12 | -$69.53M derived: sum of 3 quarters · filed 2026-03-12 | -$92.38M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$22.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$45.43M derived: sum of 2 quarters · filed 2025-11-05 | -$68.28M 10-Q · filed 2025-11-05 | -$91.76M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$23.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$46.27M 10-Q · filed 2025-08-07 | -$69.76M derived: sum of 3 quarters · filed 2025-08-07 | -$91.00M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$22.85M 10-Q · filed 2025-05-06 | -$46.34M derived: sum of 2 quarters · filed 2025-05-06 | -$67.57M derived: sum of 3 quarters · filed 2025-05-06 | -$92.47M derived: sum of 4 quarters · filed 2025-05-06 | ||||
| 2023-12-31 | -$23.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$44.72M derived: sum of 2 quarters · filed 2025-03-06 | -$69.62M derived: sum of 3 quarters · filed 2025-03-06 | -$93.72M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$21.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$46.14M derived: sum of 2 quarters · filed 2024-11-06 | -$70.23M 10-Q · filed 2024-11-06 | -$89.07M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | -$24.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$48.99M 10-Q · filed 2024-08-13 | -$67.83M derived: sum of 3 quarters · filed 2024-08-13 | -$83.16M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$24.09M 10-Q · filed 2024-05-14 | -$42.93M derived: sum of 2 quarters · filed 2024-05-14 | -$58.26M derived: sum of 3 quarters · filed 2024-05-14 | -$72.96M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | -$18.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$34.16M derived: sum of 2 quarters · filed 2024-03-19 | -$48.87M derived: sum of 3 quarters · filed 2024-03-19 | -$44.77M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | -$15.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$30.03M derived: sum of 2 quarters · filed 2023-11-08 | -$25.93M 10-Q · filed 2023-11-08 | -$39.37M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | -$14.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$10.60M 10-Q · filed 2023-08-09 | -$24.04M derived: sum of 3 quarters · filed 2023-08-09 | -$33.73M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $4.11M 10-Q · filed 2023-05-09 | -$9.34M derived: sum of 2 quarters · filed 2023-05-09 | -$19.02M derived: sum of 3 quarters · filed 2023-05-09 | -$31.80M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | -$13.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$23.13M derived: sum of 2 quarters · filed 2023-03-15 | -$35.91M derived: sum of 3 quarters · filed 2023-03-15 | -$51.05M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | -$9.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$22.46M derived: sum of 2 quarters · filed 2022-11-08 | -$37.61M 10-Q · filed 2022-11-08 | -$50.95M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$12.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$27.92M 10-Q · filed 2022-08-10 | -$41.27M derived: sum of 3 quarters · filed 2022-08-10 | -$49.12M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$15.15M 10-Q · filed 2022-05-12 | -$28.49M derived: sum of 2 quarters · filed 2022-05-12 | -$36.34M derived: sum of 3 quarters · filed 2022-05-12 | -$48.35M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$13.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$21.19M derived: sum of 2 quarters · filed 2022-03-15 | -$33.20M derived: sum of 3 quarters · filed 2022-03-15 | -$41.55M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$7.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$19.86M derived: sum of 2 quarters · filed 2021-11-10 | -$28.21M 10-Q · filed 2021-11-10 | -$35.47M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | -$12.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$20.36M 10-Q · filed 2021-08-12 | -$20.38M 10-Q · filed 2020-07-30 | -$27.62M derived: sum of 3 quarters · filed 2021-08-12 | -$22.02M derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | -$8.35M 10-Q · filed 2021-05-17 | -$15.04M 10-Q · filed 2020-05-07 | -$15.61M derived: sum of 2 quarters · filed 2021-05-17 | -$10.01M derived: sum of 3 quarters · filed 2021-05-17 | -$24.18M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | -$7.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$1.66M derived: sum of 2 quarters · filed 2021-03-12 | -$15.83M derived: sum of 3 quarters · filed 2021-03-12 | -$27.88M 10-K · filed 2021-03-12 | -$73.68M 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$8.57M derived: sum of 2 quarters · filed 2020-11-05 | -$20.62M 10-Q · filed 2020-11-05 | -$48.04M 10-Q · filed 2019-11-05 | -$11.00M derived: sum of 4 quarters · filed 2021-03-12 | |||
| 2019-06-30 | -$14.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$26.22M 10-Q · filed 2020-07-30 | -$26.39M 10-Q · filed 2019-08-14 | -$16.60M derived: sum of 3 quarters · filed 2021-03-12 | -$27.32M derived: sum of 4 quarters · filed 2021-03-12 | |||
| 2019-03-31 | -$12.05M 10-Q · filed 2020-05-07 | -$2.42M derived: sum of 2 quarters · filed 2021-03-12 | -$13.14M derived: sum of 3 quarters · filed 2021-03-12 | -$22.93M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2018-12-31 | $9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$1.09M derived: sum of 2 quarters · filed 2021-03-12 | -$10.88M derived: sum of 3 quarters · filed 2021-03-12 | -$18.18M 10-K · filed 2021-03-12 | -$35.53M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | -$10.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$20.50M derived: sum of 2 quarters · filed 2019-11-05 | -$27.80M 10-Q · filed 2019-11-05 | -$32.79M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | -$9.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$17.09M 10-Q · filed 2019-08-14 | -$22.08M derived: sum of 3 quarters · filed 2020-03-12 | -$25.93M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | -$7.30M 10-Q · filed 2019-05-15 | -$12.29M derived: sum of 2 quarters · filed 2020-03-12 | -$16.15M derived: sum of 3 quarters · filed 2020-03-12 | |||||
| 2017-12-31 | -$4.99M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$8.85M derived: sum of 2 quarters · filed 2020-03-12 | -$10.98M 10-K · filed 2020-03-12 | |||||
| 2017-09-30 | -$3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$6.00M 10-Q · filed 2018-11-13 | ||||||
| 2017-06-30 | -$2.14M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |